Nāaloxone Grant Program
Introduction
Senate Bill (SB) 833 (Chapter 30, Statutes of 2016) established a new
Naloxone Grant Program within the California Department of Public Health (CDPH)
with the goal of reducing the number of fatal overdoses in California from
opioid drugs, including prescription opioids and heroin, by increasing access to
the life-saving drug naloxone. A total of $3 million was allocated on a one-time
basis to support this program. The
Naloxone Grant Program is administered by the Safe and Active Communities Branch
(SACB).
Drug overdose (poisoning) is the leading cause of
unintentional injury death in the United States, causing more deaths than motor
vehicle crashes. Opioids ā both prescription painkillers and heroin ā are
responsible for most of those deaths. The number of
Californians affected by prescription and non-prescription opioid misuse and
overdose is substantial, with rates varying significantly across counties, and
even within counties.
Naloxone is a medication that works almost
immediately to reverse opiate overdose. Naloxone is currently a prescription
drug, but is not a controlled substance. It has few known adverse effects, no
potential for abuse, and can be rapidly administered through intramuscular
injection or nasal spray. While most professional first responders and emergency
departments are equipped with naloxone, emergency service providers may not
arrive in time to revive overdose victims. Trained and equipped
bystanders such as friends, family and other non-health
care providers (lay people) and drug users themselves can effectively respond
and reverse an opioid overdose. Given the success of bystander naloxone
programs, the CDC and the World Health Organization have recommended expanding
the availability of naloxone to lay people. For
more information on understanding how naloxone works, visit the Harm Reduction Coalition website.
Naloxone Distribution Systems: 1)
work under a standing order from a licensed clinician/medical director; 2) have
staff that are trained (or are trained to provide education to others) on
overdose prevention techniques, how to recognize an opioid overdose (signs and
symptoms), how to respond by calling 911 and providing rescue breathing,
naloxone storage and administration, and post-overdose care; 3) dispense
naloxone products; and, 4) document distribution efforts.
Laws are currently in place that
support making naloxone more readily available. For example, California Civil Code Section 1714.22 (Statutes of 2013, Chapter
707, Sec. 1) eliminates civil and criminal liability for: 1) licensed health
care providers that prescribe naloxone and issue standing orders for the
distribution of naloxone, and 2) individuals that administer naloxone to someone
suspected of experiencing an overdose after receiving it along with required
training. This law took effect on January 1,
2014.
Request
for Applications (RFA) #16-10967: Naloxone Distribution
Projects
SACB
released a non-competitive RFA on March 27, 2017, offering grants of naloxone
product (Narcan nasal spray) and funding to all 61 local health departments
(LHDs) to conduct Naloxone Distribution Projects. LHDs will provide
Narcan to local programs, agencies and community-based organizations (local
entities) within their jurisdictions that have naloxone distribution systems and
are in the best position to save lives from opioid overdose. For information
regarding this RFA, please see below.